Earnings this week : Nov 17 - 21, 25 (wk 47)

Monday (Nov 17)

• Morning: AMRK BRC JJSF JKS
• Afternoon: LFMD TCOM

Tuesday (Nov 18)

• Morning: ACM AS BIDU BRBR ENR HD JHX KLAR MDT OCSL PDD WB
• Afternoon: DLB GBDC HP LZB POWL SQM

Wednesday (Nov 19)

• Morning: BLSH DY GDS GLBE KC LOW NTES TGT TJX VIK WIX
• Afternoon: BV CPA JACK KLIC NJR NVDA ODD PANW ZTO

Thursday (Nov 20)

• Morning: ATKR BBWI ROAD J MAGN MMS SCVL VIPS WMT WMG
• Afternoon: CPRT ESTC ESE GAP INTU POST ROST UGI VEEV BULL

Friday (Nov 21)

• Morning: BJ BKE MOG.A

This week's biggest % gainers & losers : Nov 10 - 14, 25 (wk 46)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: IRWD (3.22 +67.71%), TXMD (1.92 +38.13%), RIGL (42.29 +20.16%), TBPH (17.51 +18.72%), ASMB (36.88 +18.21%), OMER (7.68 +16.54%), LXRX (1.46 +16.4%), DNLI (17.46 +16.25%), KURA (11.43 +15.92%)
• Materials: BAK (3.06 +23.39%), ALB (115.14 +18.48%), SEE (43.26 +18.04%)
• Consumer Discretionary: CHGG (1.1 +22.91%)
• Information Technology: CSIQ (33.87 +18.95%), TSEM (99.38 +18.21%), CNDT (2.06 +15.45%)
• Energy: BTE (3.15 +24.8%)
• Consumer Staples: THS (23.94 +25.67%)

This week's top % losers

• Healthcare: SGRY (15.38 -28.47%), AKBA (1.66 -18.63%), PBYI (4.91 -18.11%), ACHC (16.01 -17.94%), EVH (4.18 -15.83%), ANAB (33.97 -14.33%)
• Industrials: JELD (2.03 -21.74%), BE (110.74 -18.1%)
• Consumer Discretionary: MPAA (13.16 -24.31%), PETS (1.99 -22.73%), FUN (14.76 -18.14%), MOD (130.85 -16.33%), SNBR (3.95 -14.43%)
• Information Technology: AAOI (21.33 -25.34%), INSG (11.25 -21.11%), AVX (1.83 -16.44%)

Cidara Therapeutics (CDTX) to be acquired by Merck (MRK) for $9.2B or $221.50 per share

Cidara Therapeutics to be acquired by Merck (MRK) for $221.50 per share in cash

• Merck (MRK) agreed to acquire Cidara Therapeutics (CDTX) for $221.50/share in cash, valuing the transaction at ~$9.2B, as part of its strategy to broaden its infectious disease pipeline.
• Deal centers on CD388, a long-acting, strain-agnostic antiviral in Phase 3 (ANCHOR) for preventing influenza in high-risk individuals; the candidate has Breakthrough Therapy and Fast Track designations and showed strong efficacy in the Phase 2b NAVIGATE trial.
• CD388 combines a neuraminidase inhibitor with a proprietary Fc-antibody fragment, aiming to provide a durable prevention option beyond vaccines and traditional antivirals.
  
• Boards of both companies have approved the transaction; closing is expected in Q1 2026, pending a successful tender offer, HSR clearance, and customary conditions.

  

 

The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 38
• Incorporated in 2012 
• Based in San Diego, California
• https://www.cidara.com

Unusual Options Activity Wed 11/12/25

The following options are exhibiting notable trading, potentially indicating changing sentiment toward the underlying stocks, and/or potentially representing positioning for increased volatility.

Bullish Call Activity

• DLO Weekly Nov21 13.47 calls are seeing interest ahead of earnings tonight after the close (volume: 4.0K, open int: 1.4K, implied vol: ~104%, prev day implied vol: 68%). 4K traded in a single transaction.
• NU Weekly Nov14 16.5 calls (volume: 5.1K, open int: 4.2K, implied vol: ~47%, prev day implied vol: 41%). 1.9K traded in a single transaction. Co is confirmed to report earnings tomorrow after the close.
  
• ONON Nov 46 calls are seeing interest with the underyling stock up 17% (volume: 1.3K, open int: 4.0K, implied vol: ~46%, prev day implied vol: 43%). Co reported earnings last night.
  

Bearish Put Activity

• LCID Dec27 10 puts are seeing interest with the underlying stock down 7% (volume: 5.0K, open int: 40, implied vol: ~77%, prev day implied vol: 62%). 3K traded in a single transaction. Co priced offering of $875 mln of 7.00% convertible senior notes due 2031. Co is expected to report earnings early March.
• DIS Weekly Nov14 110 puts are seeing interest ahead of earnings tomorrow before the open (volume: 2.2K, open int: 1.4K, implied vol: ~39%, prev day implied vol: 32%)

Sentiment: The CBOE Put/Call ratio is currently: 0.79, VIX: (17.68, +0.40, +2.3%).
November 21 is options expiration -- the last day to trade November equity options.